drugset
drugset / Trial / NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500 ↗

Phase 1 Recruiting 336 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Timeline

Start
2022-06-09
Primary completion
2027-12-10
Completion
2027-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MRTX1719 Unknown — —

Indications

malignant peripheral nerve sheath tumor mesothelioma non-small cell lung carcinoma pancreatic adenocarcinoma